Archō’s Syndicated Platform for Advocacy Intelligence.
Lead with intelligence. ELAVAY is the syndicated Advocacy Intelligence platform. It shows how patient communities perceive your organization, where you lead, where gaps remain, and what must happen next. Benchmarking back to 2015 across 20+ disease states. Each year, we ask 20,000 patient advocacy organizations, professional societies, and community-based organizations to participate in ELAVAY's fielding to ensure we capture the full spectrum of patient advocacy organizations in the industry.
The ELAVAY Advocacy Intelligence study is a snapshot in time. It measures perception, never the team’s effort or impact. It is an opportunity to understand how each organization’s work is perceived, how it compares to others, and where to improve the organization while addressing the needs of patient advocates and patients.
Reach is not respect
Reach is not respect. ELAVAY 2026 measures pharmaceutical and biotechnology companies two ways: reach (the breadth of advocacy attention a company earns) and regard (the quality of the relationship as advocacy organizations rate it). The winners are not the same. Scale buys reach. It does not buy respect.
Bring both scores into the room. That is how peers win budget and earn a seat where decisions get made.
Three cuts. Same picture.
Lowest-scoring attribute
In ELAVAY 2026, access to company leadership is the lowest-scoring relationship attribute among all respondents, at 5.07 on a 7-point scale. It ranks last in every 2026 cut (all-respondent 5.07; mental health 5.73; oncology 5.30).
Widest demand-supply gap
In ELAVAY 2026, systemic barriers to equity is the widest demand-supply gap among all respondents: industry support 3.09, advocacy desire 5.22, gap +2.13 on a 7-point scale. It is the largest such gap in every measured 2026 cut (all-respondent +2.13; mental health +2.93; oncology +1.93). The diabetes cut does not field demand tables.
A deficit in every area
In ELAVAY 2026, advocacy interest exceeds industry support in all 30 program areas. Every area shows a deficit; mean gap 1.30 points.
Request a briefing for the 2026 cuts. Walk in with the script leadership funds. We do not publish a leaderboard.
Six ways to see clearly
Cross-industry benchmarks. Disease-state depth. Custom cuts built for the question leadership is actually asking.
Benchmark Report
Where you stand on engagement, trust, and impact. The brief leadership can fund.
Disease-State Reports
The disease-state cut. What that community will work with you on.
Health Equity & SDOH
Where equity and SDOH change access, trust, and outcomes.
Echos in Research
Where the patient voice shows up in research, and where it is missing.
Policy Pulse
Where policy pressure is moving. What advocates expect next.
BioAdvocate Benchmark
A separate study. Size, budget, alignment, focus, and tactics of the patient advocacy function across pharma, biotech, and medical device.
Signal you can trust
Disciplined fielding. Findings that hold in front of leadership.
Prioritize
Define the topics and communities that matter most this cycle.
Survey
Invite-only fielding to verified advocacy organizations and leaders.
Interview
Qualitative depth that explains the "why" behind the numbers.
Validate
Data-integrity checks and weighting before anything ships.
Built for life-science teams
For patient advocacy, corporate affairs, and franchise leaders who have to take this into the room and make it move a decision.
See the report. Then turn it into influence.
ELAVAY is the syndicated research. Advisory turns the patient voice into decisions leadership funds. The data shows where to act, and we help you act on it.
See Advisory & ActivationReal ELAVAY findings, from non-medical switching impact to copay-education gaps and literacy barriers, make the case better than any pitch. Explore a sample.
View sample intelligenceProduct details live at elavay.com.
What advocacy leaders do with ELAVAY.
The ELAVAY Survey was the foundation of our continued defense as the industry's number one patient advocacy function for over ten years.
The feedback from the survey is quite insightful. We all work hard, but until you know the community's perception, you really don't know if you are effective. The survey provides feedback, and the granular comments offer better insights about their challenges.
Pick your starting point
Every path starts with a short call with Matt Toresco.
Your ELAVAY standing
Walk through where you lead, where gaps remain, and what the 2026 cuts mean for your team.
Book a report briefingYour question, answered
Scope a cut built for the decision leadership has to make next.
Book a scoping callAdvocacy Influence Diagnostic
Step one: book a short intro. Step two: take the diagnostic. Learn more on the AID page.
Book an introTake the AID surveyWalk in ready
Request an ELAVAY briefing and see what the patient community already knows about your organization.